Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
Pharmaceutics · 09.05.2026 · 18 (5) · 584
DOI: 10.3390/pharmaceutics18050584 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.05.2026. Verfasst von Elda Cristina Villaseñor-Tapia und 3 weiteren Autor:innen. Beteiligte Einrichtung: EMCS, Tecnologico de Monterrey, Zapopan 45201, Jalisco, Mexico. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tecnológico de Monterrey.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent global health concern driven by metabolic imbalance and excess caloric intake, leading to hepatic steatosis, inflammation, and fibrosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, or hepatocellular carcinoma. Current management relies primarily on lifestyle interventions and, in advanced stages, pharmacological therapies; however, long-term outcomes remain limited due to variable efficacy and poor sustainability. Recent advances in pharmacotherapy, including GLP-1 receptor agonists, THR-β agonists and SGLT2 inhibitors, have shown clinically meaningful improvements in metabolic parameters and hepatic steatosis, although their impact on fibrosis and long-term disease modification remains uncertain. In parallel, genomic and nanotechnology-based strategies (such as RNA-based therapies and nanoparticle delivery systems) have emerged as promising approaches to enhance drug stability, targeting, and therapeutic precision. Despite these advances, most emerging strategies remain at preclinical or early translational stages, with significant challenges related to safety, scalability, regulatory approval, and long-term efficacy. In this context, this review provides an integrative synthesis of pharmacological, genomic, and nanotechnology-based therapies, highlighting their mechanisms, limitations, and translational potential. Future research should focus on well-designed clinical trials, standardized evaluation frameworks, and the development of personalized therapeutic approaches. The convergence of these strategies may enable more effective and durable interventions for MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EMCS, Tecnologico de Monterrey, Zapopan 45201, Jalisco, Mexico.
- Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, CUCS, Guadalajara 44340, Jalisco, Mexico.
ORCID-Profile: Elda Cristina Villaseñor-Tapia, Adriana Franco-Acevedo, Juan Armendariz-Borunda
Förderung
- Tecnológico de Monterrey
Zitieren
APA
Villaseñor-Tapia, E. C., Franco-Acevedo, A., Rosas-Campos, R., & Armendariz-Borunda, J. (2026). Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD. Pharmaceutics, 18(5), 584. https://doi.org/10.3390/pharmaceutics18050584
Vancouver
Villaseñor-Tapia EC, Franco-Acevedo A, Rosas-Campos R, Armendariz-Borunda J. Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD. Pharmaceutics. 2026;18(5):584. doi:10.3390/pharmaceutics18050584
BibTeX
@article{VillaseorTapia2026,
author = {Villaseñor-Tapia, Elda Cristina and Franco-Acevedo, Adriana and Rosas-Campos, Rebeca and Armendariz-Borunda, Juan},
title = {Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {584},
doi = {10.3390/pharmaceutics18050584}
}
EUVIMED